Antiphospholipid syndrome (APS) is generally considered a chronic condition, but the antibodies that define it don’t always stick around. In a large longitudinal study, 44% of patients with confirmed antiphospholipid antibodies saw their antibody profiles become transient over time, meaning they no longer consistently tested positive. Whether that translates to the syndrome truly “going away” depends on several factors: what triggered the antibodies in the first place, how many types of antibodies you tested positive for, and how high your levels were.
The short answer is that some people do become antibody-negative over time, and a smaller subset may eventually be candidates for stopping treatment. But for many others, APS requires lifelong management.
Persistent vs. Transient Antibodies
Not everyone diagnosed with antiphospholipid antibodies carries them permanently. A study tracking 200 patients over time found that 56% maintained a persistent antibody profile, while 44% shifted to a transient pattern. The biggest predictor of whether antibodies would stick around was how many types tested positive at diagnosis. People who were “triple positive,” meaning they had all three major antibody types (lupus anticoagulant, anticardiolipin, and anti-beta-2 glycoprotein I), were 78 times more likely to remain persistently positive compared to those with a single antibody type.
On the other hand, people who tested positive for only one antibody type, particularly lupus anticoagulant alone or anticardiolipin alone, were significantly more likely to become negative over time. Low-titer antibody positivity, especially when transient, carries a low risk of clinical problems like blood clots or pregnancy complications. These low-level results are sometimes linked to infections, medications, or other temporary triggers rather than true autoimmune APS.
Across the broader literature, the rate at which antiphospholipid antibodies disappear during follow-up ranges from about 9% to 59% of patients, a wide spread that reflects differences in study populations, antibody types tested, and how long people were tracked.
When Positive Antibodies Don’t Mean APS
A positive antibody test doesn’t automatically mean you have antiphospholipid syndrome. To meet the diagnostic criteria, antibodies must be present on at least two separate occasions, tested at least 12 weeks apart. This waiting period exists specifically because many things can cause a temporary spike in antiphospholipid antibodies.
Infections are the most common culprit. Antiphospholipid antibodies were first discovered in patients with syphilis, and since then they’ve been linked to a long list of infections: HIV, hepatitis C, Epstein-Barr virus, cytomegalovirus, tuberculosis, Lyme disease, and COVID-19. During the pandemic, a significant number of hospitalized COVID patients tested positive for these antibodies, but most did not develop actual APS. The antibodies were generally transient and disappeared as the infection resolved.
Infection-triggered antibodies tend to look different from autoimmune APS antibodies in several ways. They’re typically low-titer, often IgM class rather than IgG, and they usually don’t bind to beta-2 glycoprotein I (one of the key targets in true APS). They also tend to show up during or immediately after an infection rather than persisting for months. In some infections like Lyme disease, up to 80% of patients tested positive for antiphospholipid antibodies in certain studies, yet only about 10% developed blood clots.
If your positive antibody test was first drawn during an acute illness, there’s a real chance a repeat test 12 weeks later will come back negative, meaning you never had APS in the first place.
Can Treatment Make APS Go Into Remission?
Current treatments for APS focus on preventing blood clots rather than eliminating the underlying antibodies. Blood thinners remain the standard approach, and they work well at reducing clot risk, but they don’t address the immune system’s production of problematic antibodies.
Hydroxychloroquine, a medication commonly used for lupus, has shown some promise. Long-term use has been associated with decreased antibody levels in people who carry antiphospholipid antibodies but haven’t yet had clotting events. This is particularly relevant for people whose APS is connected to lupus or another autoimmune condition.
Researchers have also explored therapies that target the immune cells producing these antibodies. Rituximab, which depletes a type of immune cell called B-cells, has shown clinical benefits for some APS patients, particularly those with low platelet counts that don’t respond to other treatments. In one case series, patients achieved remission lasting nearly four years after a single course. However, rituximab doesn’t reliably eliminate antiphospholipid antibodies themselves. After 18 months in one study, none of the patients who were positive for lupus anticoagulant or certain antibody classes became seronegative, even though some saw modest reductions in levels. This suggests that B-cells contribute to APS symptoms in ways beyond just producing antibodies.
Newer experimental approaches, including drugs that target antibody-producing plasma cells directly, have shown temporary reductions in antibody levels. One case report documented a notable decline in antibodies lasting over 100 days after treatment. But these remain early-stage findings, not established therapies.
What Happens If Your Antibodies Disappear
If repeat testing shows your antiphospholipid antibodies have become negative, you might wonder whether you can stop treatment. This is one of the more debated questions in APS management, and the honest answer is that there’s no strong evidence base to guide the decision.
Some experts have proposed that stopping blood thinners could be considered in a narrow group of patients: those who had only a single, non-life-threatening clotting event that occurred alongside another temporary risk factor (like oral contraceptives, pregnancy, or surgery), and who have been stable without further events for at least two years. Even in these cases, the decision requires careful individual risk assessment and a thorough conversation with your hematologist or rheumatologist.
For people with APS connected to an underlying autoimmune disease like lupus, or those with additional cardiovascular risk factors, most experts favor continuing blood thinners indefinitely, even if antibody tests turn negative. The concern is that antibodies can fluctuate, and a negative test today doesn’t guarantee they won’t return.
What Determines Your Outlook
Your likelihood of seeing APS “go away” depends heavily on your specific situation. Several factors tilt the odds:
- Number of antibody types: If you tested positive for only one antibody type at low levels, your chances of becoming negative are meaningfully higher than someone with double or triple positivity.
- Antibody levels: Low-titer positivity is more likely to be transient. Medium-to-high titers tend to persist and carry greater clinical risk.
- Trigger: If your antibodies appeared during an infection, they may resolve completely once the infection clears. Autoimmune-driven antibodies are more likely to persist.
- Associated conditions: APS linked to lupus or other autoimmune diseases tends to follow a more chronic course, though treating the underlying condition can help reduce antibody levels.
- History of clotting events: People who have had multiple clots or severe complications are generally managed as having a lifelong condition regardless of what happens to their antibody levels.
For people with confirmed, persistently positive, high-titer, or triple-positive antibodies and a history of clotting, APS is realistically a lifelong diagnosis that requires ongoing treatment. For those with a single low-titer antibody that appeared in the context of an infection or medication, the antibodies may well disappear entirely, and the diagnosis may not apply long-term. Most people fall somewhere between these two extremes, which is why regular follow-up testing and individualized care matter so much in this condition.